$LLY vs $NVO: Medicare GLP Bridge program is a boon to Lilly. Novo? Not so much...
retained text
According to Lilly CEO Dave Ricks 700,000 new seniors started a GLP after the Medicare GLP Bridge Program started in July... Lilly captures 70% of them... Here is the latest data on GLP prescribing trends and you can clearly see that $LLY is in fact the main beneficiary of the Medicare GLP Bridge Program... [https://www.medrxiv.org/content/10.1101/2025.03.06.25323524v7.full.pdf](https://www.medrxiv.org/content/10.1101/2025.03.06.25323524v7.full.pdf) Ozempic has been in a steady decline since 2024 Wegovy had a big bump early in the year when the pill came out, but has been flat since then Mounjaro has been straight up and to the right with no end in sight... Zepbound was up and to the right, then had a huge bump from the start of the Medicare GLP Bridge Program Not surprising that if you offer a superior drug for the same price, 7 out of 10 will go that route...
document fetched 2026-10-30 00:33 · canonical https://reddit.com/r/stocks/comments/1xi5mmv/lly_vs_nvo_medicare_glp_bridge_program_is_a_boon